OBJECTIVE: To investigate whether expression of the four members of the neurotrophin (NT) family and their four corresponding receptors is related to synovial inflammation in patients with spondyloarthritis (SpA). MATERIAL AND METHODS: Synovial fluid (SF) and serum NTs and their receptors were measured by ELISA. Immunohistochemistry was used for synovial tissue biopsy specimens from patients with SpA, rheumatoid arthritis, and osteoarthritis (OA). In SpA synovium, immunoreactivity of the receptors trkA and NGFRp75 was also assessed before and after 12 weeks of treatment with the monoclonal anti-tumour necrosis factor alpha antibody, infliximab. RESULTS: mRNA transcripts of all NTs and receptors were expressed in the inflamed synovium. At the protein level, brain derived neurotrophic factor and NT-3 were significantly higher in the SF of patients with SpA than in those with OA. In contrast, ELISA of serum samples showed that the highest member in SpA was NT-4. Immunohistochemistry demonstrated that the NT receptors trkA and NGFRp75 were highly expressed in the inflamed synovium of patients with SpA, correlating with vascularity and lymphoid aggregates, respectively. Additionally, immunoreactivity of both receptors was significantly decreased after infliximab treatment. CONCLUSIONS: NTs and their receptors are expressed in inflamed peripheral joints of patients with SpA. Their expression is not constitutive but related to inflammation and they may be involved in the local disease processes.
OBJECTIVE: To investigate whether expression of the four members of the neurotrophin (NT) family and their four corresponding receptors is related to synovial inflammation in patients with spondyloarthritis (SpA). MATERIAL AND METHODS: Synovial fluid (SF) and serum NTs and their receptors were measured by ELISA. Immunohistochemistry was used for synovial tissue biopsy specimens from patients with SpA, rheumatoid arthritis, and osteoarthritis (OA). In SpA synovium, immunoreactivity of the receptors trkA and NGFRp75 was also assessed before and after 12 weeks of treatment with the monoclonal anti-tumour necrosis factor alpha antibody, infliximab. RESULTS: mRNA transcripts of all NTs and receptors were expressed in the inflamed synovium. At the protein level, brain derived neurotrophic factor and NT-3 were significantly higher in the SF of patients with SpA than in those with OA. In contrast, ELISA of serum samples showed that the highest member in SpA was NT-4. Immunohistochemistry demonstrated that the NT receptors trkA and NGFRp75 were highly expressed in the inflamed synovium of patients with SpA, correlating with vascularity and lymphoid aggregates, respectively. Additionally, immunoreactivity of both receptors was significantly decreased after infliximab treatment. CONCLUSIONS: NTs and their receptors are expressed in inflamed peripheral joints of patients with SpA. Their expression is not constitutive but related to inflammation and they may be involved in the local disease processes.
Authors: M Reinshagen; H Rohm; M Steinkamp; K Lieb; I Geerling; A Von Herbay; G Flämig; V E Eysselein; G Adler Journal: Gastroenterology Date: 2000-08 Impact factor: 22.682
Authors: E Garaci; M C Caroleo; L Aloe; S Aquaro; M Piacentini; N Costa; A Amendola; A Micera; R Caliò; C F Perno; R Levi-Montalcini Journal: Proc Natl Acad Sci U S A Date: 1999-11-23 Impact factor: 11.205
Authors: Leen De Rycke; Dominique Baeten; Dirk Foell; Elli Kruithof; Eric M Veys; Johannes Roth; Filip De Keyser Journal: J Pathol Date: 2005-05 Impact factor: 7.996
Authors: D Baeten; P Demetter; C Cuvelier; F Van Den Bosch; E Kruithof; N Van Damme; G Verbruggen; H Mielants; E M Veys; F De Keyser Journal: Ann Rheum Dis Date: 2000-12 Impact factor: 19.103
Authors: Helena Alessi; Lívia Almeida Dutra; Lília A Maria; Paula C Coube; Karina Hoshino; Fabiano F de Abrantes; Fernanda C Lopes; Alexandre Wagner S de Souza; Cristiane Kayser; Orlando G P Barsottini Journal: Clin Rheumatol Date: 2021-09-19 Impact factor: 2.980
Authors: Christian Barthel; Nataliya Yeremenko; Roland Jacobs; Reinhold E Schmidt; Michael Bernateck; Henning Zeidler; Paul-Peter Tak; Dominique Baeten; Markus Rihl Journal: Arthritis Res Ther Date: 2009-06-02 Impact factor: 5.156